睿知中国医院研究地图
候选清单

即将招募乳腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由浙江省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06140576,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 70 岁;性别:仅女性

    登记记录的入选字段

  2. According to the definition of the latest ASCO/CAP guidelines, recurrent metastatic triple negative invasive breast cancer confirmed by histopathology meets the following conditions according to recent and previous pathological results: HER2 negative: IHC 0/1+or IHC2+but ISH is negative; ER negative: IHC<1%, PR negative: IHC<1%.

    入选标准第 2 条

  3. Patients who have received (new) adjuvant chemotherapy need to make progress at least 6 months after the end of the last adjuvant chemotherapy.

    入选标准第 3 条

    Active or symptomatic brain metastasis There are metastases in the midbrain, pons, medulla oblongata, or spinal cord. Meningeal metastasis; Symptoms related to the nervous system, such as increased intracranial pressure and abnormal neurological function; Received surgical treatment within 28 days of enrollment, received whole brain radiotherapy within 14 days, or received stereotactic radiotherapy within 7 days; If the patient only has supratentorial and/or cerebellar metastases and has undergone local treatment (surgery/radiotherapy for all known lesions), clinical stability is at least 2 weeks after completion of treatment, imaging shows no disease progression or bleeding, and does not need to receive hormone treatment or receive ≤ 10mg/day of prednisone or equivalent dose hormone treatment within 14 days of initial administration, patients can participate in the study.

    排除标准第 2 条

    Within 14 days prior to enrollment, receive systematic anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biotherapy, or tumor embolization);

    排除标准第 4 条

    Previously received treatment with PD-1/PD-L1 antibodies, CTLA-4 antibodies, or other anti angiogenic drugs (including monoclonal antibodies, TKI) targeting PD-1/PD-L1;

    排除标准第 7 条

    Subjects who have received systemic immunostimulatory therapy (including but not limited to interferon or interleukin-2, including immunostimulators in clinical research) within 4 weeks prior to the first administration;

    排除标准第 20 条

    Subjects who have received systemic immunosuppressive therapy (including but not limited to glucocorticoids, azathioprine, methotrexate, thalidomide, and anti-tumor factor drugs) within 2 weeks before the first administration. Excluding systemic corticosteroids with nasal spray and inhaled corticosteroids or physiological doses (i.e. other corticosteroids with physiological doses not exceeding 10mg/d prednisone or equivalent);

    排除标准第 21 条

  4. ECOG score 0-1.

    入选标准第 4 条

  5. According to RECIST 1.1 standard, at least one measurable lesion exists.

    入选标准第 6 条

  6. The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgical procedures (tissue biopsy and central venous catheter placement via peripheral vein puncture required for diagnosis are allowed);

    排除标准第 10 条

    Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); Active hepatitis (hepatitis B, defined as HBV-DNA ≥ 30 copies/ml; hepatitis C, defined as HCV-RNA higher than the detection limit of the analytical method) or co infection of hepatitis B and hepatitis C; Autoimmune hepatitis;

    排除标准第 14 条

  7. Women of childbearing age must undergo a serum pregnancy test within 7 days before enrollment, with a negative result, and are willing to use a medically recognized and efficient contraceptive method during the study period and within 3 months after the last administration of the study medication.

    入选标准第 9 条

    Pregnant and lactating female patients, those with fertility and positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures throughout the entire trial period.

    排除标准第 23 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06140576,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Breast cancer patients aged ≥ 18 years and ≤ 70 years.
  2. According to the definition of the latest ASCO/CAP guidelines, recurrent metastatic triple negative invasive breast cancer confirmed by histopathology meets the following conditions according to recent and previous pathological results: HER2 negative: IHC 0/1+or IHC2+but ISH is negative; ER negative: IHC<1%, PR negative: IHC<1%.
  3. Patients who have received (new) adjuvant chemotherapy need to make progress at least 6 months after the end of the last adjuvant chemotherapy.
  4. ECOG score 0-1.
  5. In the stage of recurrence and metastasis, without receiving systematic anti-tumor treatment;
  6. According to RECIST 1.1 standard, at least one measurable lesion exists.
  7. The expected survival period is not less than 3 months.
  8. The functional level of organs must meet the following requirements:
  9. Women of childbearing age must undergo a serum pregnancy test within 7 days before enrollment, with a negative result, and are willing to use a medically recognized and efficient contraceptive method during the study period and within 3 months after the last administration of the study medication.
  10. The subjects voluntarily joined this study and signed an informed consent form.

排除标准:Exclusion Criteria:

  1. Tumor related symptoms and treatment
  2. Active or symptomatic brain metastasis There are metastases in the midbrain, pons, medulla oblongata, or spinal cord. Meningeal metastasis; Symptoms related to the nervous system, such as increased intracranial pressure and abnormal neurological function; Received surgical treatment within 28 days of enrollment, received whole brain radiotherapy within 14 days, or received stereotactic radiotherapy within 7 days; If the patient only has supratentorial and/or cerebellar metastases and has undergone local treatment (surgery/radiotherapy for all known lesions), clinical stability is at least 2 weeks after completion of treatment, imaging shows no disease progression or bleeding, and does not need to receive hormone treatment or receive ≤ 10mg/day of prednisone or equivalent dose hormone treatment within 14 days of initial administration, patients can participate in the study.
  3. Uncontrolled moderate to large amounts of pleural effusion, intraperitoneal effusion, or pericardial effusion that require repeated drainage;
  4. Within 14 days prior to enrollment, receive systematic anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biotherapy, or tumor embolization);
  5. Imaging examination shows that the tumor invades large blood vessels, or researchers determine that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
  6. Subjects with uncontrollable or symptomatic hypercalcemia (>1.5mmol/L ionic calcium concentration or>12mg/dL serum calcium concentration or serum calcium (albumin corrected) concentration>ULN); Symptomatic hypercalcemia that may require further bisphosphate treatment;
  7. Previously received treatment with PD-1/PD-L1 antibodies, CTLA-4 antibodies, or other anti angiogenic drugs (including monoclonal antibodies, TKI) targeting PD-1/PD-L1;
  8. Combined diseases/medical history
  9. Having previously received any systematic anti-tumor treatment or local treatment (including surgery and radiation therapy) for other malignant tumors, excluding various cured malignant tumors such as in situ cancer, cervical cancer, basal cell carcinoma or squamous cell carcinoma, thyroid cancer, etc;
  10. The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgical procedures (tissue biopsy and central venous catheter placement via peripheral vein puncture required for diagnosis are allowed);
  11. Subjects with any known or suspected autoimmune diseases, except for those who only require hormone replacement therapy for hypothyroidism caused by autoimmune thyroiditis; Subjects with stable type I diabetes whose blood sugar is controlled;
  12. Interstitial lung disease, non infectious pneumonia or uncontrollable systemic diseases (such as diabetes, pulmonary fibrosis and acute pneumonia);
  13. A history of receiving live or attenuated vaccines within 28 days prior to the first study medication, or an estimated period of receiving live or attenuated vaccines during the study period;
  14. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); Active hepatitis (hepatitis B, defined as HBV-DNA ≥ 30 copies/ml; hepatitis C, defined as HCV-RNA higher than the detection limit of the analytical method) or co infection of hepatitis B and hepatitis C; Autoimmune hepatitis;
  15. Severe infections, including but not limited to bacteremia, severe pneumonia, etc. that require hospitalization treatment, exist within 4 weeks before the first administration; Or there is an active infection of CTCAE ≥ 2 level that requires systemic antibiotic treatment within 2 weeks before the first administration, or an unexplained fever>38.5 ° C during the screening period/before the first administration (according to the researcher's judgment, fever caused by tumor can be included); There is evidence of active tuberculosis infection within one year before administration;
  16. Subjects who have previously received or are preparing to receive allogeneic bone marrow transplantation or solid organ transplantation;
  17. Peripheral neuropathy ≥ level 2;
  18. Serious heart disease or discomfort, including but not limited to the following diseases:
  19. Research and treatment related
  20. Subjects who have received systemic immunostimulatory therapy (including but not limited to interferon or interleukin-2, including immunostimulators in clinical research) within 4 weeks prior to the first administration;
  21. Subjects who have received systemic immunosuppressive therapy (including but not limited to glucocorticoids, azathioprine, methotrexate, thalidomide, and anti-tumor factor drugs) within 2 weeks before the first administration. Excluding systemic corticosteroids with nasal spray and inhaled corticosteroids or physiological doses (i.e. other corticosteroids with physiological doses not exceeding 10mg/d prednisone or equivalent);
  22. Known allergies to the study drug or any of its excipients; Or have experienced severe allergic reactions to other monoclonal antibodies;
  23. Pregnant and lactating female patients, those with fertility and positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures throughout the entire trial period.
  24. Have a clear history of neurological or mental disorders, including epilepsy or dementia, and the subject is known to have a history of abuse of psychotropic substances, alcohol or drug use;
  25. The researcher believes that the patient is not suitable to participate in any other situation of this study.

引自 ClinicalTrials.gov, NCT06140576, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06140576,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06140576